These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20350654)

  • 1. Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets.
    Lam A; Shah S; Paparello J
    Dis Mon; 2010 Apr; 56(4):215-32. PubMed ID: 20350654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets.
    Lam A; Shah S; Paparello J
    Am J Ther; 2008; 15(3):278-86. PubMed ID: 18496265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anemia in chronic kidney disease and its cardiovascular implications].
    Cases A; Coll E; Collado S
    Med Clin (Barc); 2009 May; 132 Suppl 1():38-42. PubMed ID: 19460479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification.
    Saab G; Whaley-Connell AT; Khanna R; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):107-12. PubMed ID: 19124399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic kidney disease: therapy and care].
    Noel N; Gaha K; Rieu P
    Rev Prat; 2012 Jan; 62(1):43-51. PubMed ID: 22335066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses.
    Lucas SM; Nuss G; Stern J; Lotan Y; Sagalowsky AI; Cadeddu JA; Raj GV
    Cancer; 2008 Nov; 113(10):2681-6. PubMed ID: 18853420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention and treatment of secondary hyperparathyroidism in CKD].
    Gueiros JE; Hernandes FR; Karohl C; Jorgetti V;
    J Bras Nefrol; 2011 Apr; 33 Suppl 1():7-14. PubMed ID: 21655856
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients.
    Tanaka M; Komaba H; Fukagawa M
    Ther Apher Dial; 2018 Jun; 22(3):242-245. PubMed ID: 29767854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaemia and mineral bone disorder in chronic kidney disease: a review of the current literature and implications for clinical nursing practice.
    Limrick C; McNichols-Thomas C
    J Ren Care; 2009 Mar; 35 Suppl 1():94-100. PubMed ID: 19222739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperparathyroidism in patients on long-term hemodialysis].
    Rodosskaia NK; Orlova II; Brazhnikova VV
    Klin Med (Mosk); 2009; 87(4):68-70. PubMed ID: 19514326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the management of chronic kidney disease in Uruguay: a National Renal Healthcare Program.
    Schwedt E; Solá L; Ríos PG; Mazzuchi N;
    Nephron Clin Pract; 2010; 114(1):c47-59. PubMed ID: 19816043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the management of chronic kidney disease.
    Rivera JA; O'Hare AM; Harper GM
    Am Fam Physician; 2012 Oct; 86(8):749-54. PubMed ID: 23062158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CE: Continuing Education Article: MANAGEMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE.
    Chamney M; Pugh-Clarke K; Kafkia T; Wittwer I
    J Ren Care; 2010 Jun; 36(2):102-11. PubMed ID: 20591006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early diagnosis of chronic kidney disease. New insights into creatinine and proteinuria].
    Brandenburg V; Floege J
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():158-62. PubMed ID: 16802544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia development and cardiovascular risk management in nonanemic stage 3 chronic kidney disease.
    Portolés J; Castelao AM; Gorriz JL; Tato AM; de Alvaro F
    Ren Fail; 2009; 31(10):869-75. PubMed ID: 20030520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data.
    Rasu RS; Manley HJ; Crawford T; Balkrishnan R
    Clin Ther; 2007 Jul; 29(7):1524-34. PubMed ID: 17825703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.